Bleeding disorders:

Indications for Aminocaproic Acid Injection:

Bleeding associated with fibrinolysis.


4–5g (in 250mL of diluent) by IV infusion during the 1st hour, then 1g/hour (in 50mL of diluent) for 8 hours or until bleeding is controlled.


Not recommended.


Active intravascular clotting process. Disseminated intravascular coagulation without concomitant heparin.


Upper urinary tract bleeding: not recommended. Cardiac, hepatic or renal disease. Risk of myopathy with long-term use; monitor creatine phosphokinase (CPK); discontinue if CPK rises. Avoid rapid IV administration. Neonates. Pregnancy (Cat.C). Nursing mothers.

Pharmacologic Class:



Avoid concomitant Factor IX complex or Anti-inhibitor Coagulant concentrates; may increase thrombosis risk.

Adverse Reactions:

Inj site reactions, bradycardia, hypotension, GI upset, edema, headache, malaise, CNS effects, thrombosis, others; rare: myopathy.

How Supplied:

Tabs—100; Oral soln—473mL; Inj—contact supplier